cytotoxic T cell

(redirected from CD8 T-cell)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
  • noun

Synonyms for cytotoxic T cell

T cell with CD8 receptor that recognizes antigens on the surface of a virus-infected cell and binds to the infected cell and kill it

References in periodicals archive ?
Data generated using Poly-ICR, in combination with a tumor-associated antigen, have demonstrated that the addition of the adjuvant potently increases the antigen-specific CD8 T-cell levels, which correlated with regression of tumors and prevention of tumor growth in mouse models.
Direct comparisons between virus-specific CD4 and CD8 T-cell numbers within individual vaccinees revealed dynamic and independently regulated changes in T-cell memory over time," they wrote.
We have developed a Whole Blood Capcellia CD4/CD8 assay for the determination of human CD4 and CD8 T-cell counts.
RXi is developing NeuVax, a CD8 T-cell eliciting immunotherapy, for the adjuvant treatment of low to intermediate HER2 expressing breast cancer.
today announced results from a preclinical trial of IAB22M2C, the company's proprietary CD8 T-cell imaging agent, demonstrating detection of CD8 T-cell distribution as a measure of immune response.
Subsequent sophisticated analyses of T-cell activation and proliferation in people with HIV showed that CD4 and CD8 T-cell activations are tightly correlated, confirming that immune activation does not reflect an attempt by the immune system to replace CD4 T cells killed by HIV.
At early time points ranging from 27 days to 7 years after vaccination, nearly all volunteers possessed strong CD4 and CD8 T-cell responses.
Median CD4 and CD8 T-cell counts were 272 and 554 cell/mm3 at baseline, increasing to 679 and 986 cells/mm3 at week 12, respectively.
Immunohistochemistry analyses of lesional skin biopsy specimens from treated patients showed a significant increase in the numbers of infiltrating CD8 T-cell subset markers and T-cell intracytoplasmic antigen-1 cytolytic granule markers.
The median CD4 and CD8 T-cell increases per mm3 over baseline, from 240 to 563 (135%) and from 659 to 1210 (65%), respectively, at the 20mcg/kg dose, suggest the potential of CYT107 to play a significant role in HIV therapy and represent part of the rationale for initiating the INSPIRE 2 study to further explore the immunological properties of CYT107.
The proprietary system allows the secretion of the antigen, together with an immunological adjuvant which has been demonstrated to be required for optimal induction of CD8 T-cell responses by recombinant Salmonella based bacterial vaccines.
Importantly, 48 weeks after initiation of this IL-7 short course of therapy, patients treated at the 10 microgram/kg dose level showed a median percent increase in CD4 and CD8 T-cell counts (cells/microliters) of 75% and 58%, respectively, from baseline levels.
These vaccine candidates will be evaluated for their ability to generate the type of immune responses, CD8 T-cell responses, in mice and nonhuman primates that are expected to lead to protection.
Next-generation HIV vaccine achieves seven-fold increase (7% to 52%) in response rate of CD8 T-cells when delivered with electroporation; robust CD4 or CD8 T-cell responses observed in 89% of subjects